These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16800251)

  • 1. Trastuzumab in metastatic breast cancer.
    Tomao F; Miele E; Spinelli GP; Russillo M; La Ferla G; Tomao S
    Eur J Gynaecol Oncol; 2006; 27(3):247-9. PubMed ID: 16800251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.
    Arteaga CL
    Breast Cancer Res; 2003; 5(2):96-100. PubMed ID: 12631388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
    McKeage K; Perry CM
    Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab and breast cancer: developments and current status.
    Tokunaga E; Oki E; Nishida K; Koga T; Egashira A; Morita M; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2006 Jun; 11(3):199-208. PubMed ID: 16850126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu.
    Stein S; DeMichele A; Domchek S; Fox K
    Clin Breast Cancer; 2004 Jan; 4 Suppl 3():S117-20. PubMed ID: 14754469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
    Huang Y; Fu P; Fan W
    Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer.
    Plosker GL; Keam SJ
    BioDrugs; 2006; 20(4):259-62. PubMed ID: 16831025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.
    Kabe KL; Kolesar JM
    Am J Health Syst Pharm; 2006 Mar; 63(6):527-33. PubMed ID: 16522889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer].
    Ikeda M; Kurebayashi J; Sonoo H; Oota Y; Fujii S; Shimo T; Miyake A; Seki M; Souda M; Nomura T; Yamamoto Y; Shiiki S; Nakashima K; Tanaka K
    Gan To Kagaku Ryoho; 2009 May; 36(5):773-7. PubMed ID: 19461176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab-based combinations in metastatic breast cancer: how to make a choice.
    Jahanzeb M
    Clin Breast Cancer; 2003 Apr; 4(1):28-38. PubMed ID: 12744756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy by trastuzumab with 5'-deoxy-5-fluorouridine and cyclophosphamide in patients with metastatic breast cancer.
    Saito Y; Suzuki Y; Tokuda Y
    Tokai J Exp Clin Med; 2009 Sep; 34(3):106-11. PubMed ID: 21319009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.